Orthophosphate increases the efficiency of slow muscle-myosin isoform in the presence of omecamtiv mecarbil
Omecamtiv mecarbil is a small molecule effector under clinical trial for the treatment of systolic heart failure. Here the authors define the molecular mechanisms of its inotropic action and find it can increase the efficiency of contraction in muscle fibres when the orthophosphate concentration ris...
Guardado en:
Autores principales: | Serena Governali, Marco Caremani, Cristina Gallart, Irene Pertici, Ger Stienen, Gabriella Piazzesi, Coen Ottenheijm, Vincenzo Lombardi, Marco Linari |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a1356051549946cab751e8490d8aee60 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil
por: Vicente J. Planelles-Herrero, et al.
Publicado: (2017) -
Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke
por: Michael S. Woody, et al.
Publicado: (2018) -
Evaluation of drug‐drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically‐based pharmacokinetic model
por: Ashit Trivedi, et al.
Publicado: (2021) -
Distinct functional interactions between actin isoforms and nonsarcomeric myosins.
por: Mirco Müller, et al.
Publicado: (2013) -
Myosin isoform expressed in metastatic prostate cancer stimulates cell invasion
por: Ivan V. Maly, et al.
Publicado: (2017)